1. Home
  2. HAWK vs RAPP Comparison

HAWK vs RAPP Comparison

Compare HAWK & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HawkEye 360 Inc. Common Stock

HAWK

HawkEye 360 Inc. Common Stock

HOLD

Current Price

$12.33

Market Cap

1.2B

Sector

Technology

ML Signal

HOLD

Logo Rapport Therapeutics Inc.

RAPP

Rapport Therapeutics Inc.

HOLD

Current Price

$26.10

Market Cap

1.4B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
HAWK
RAPP
Founded
2015
2022
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.4B
IPO Year
2026
2024

Fundamental Metrics

Financial Performance
Metric
HAWK
RAPP
Price
$12.33
$26.10
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
16
Target Price
$29.10
★ $62.71
AVG Volume (30 Days)
★ 1.3M
731.2K
Earning Date
11-12-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 24.34
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$84.65
N/A
Revenue Next Year
$25.27
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.41
$23.75
52 Week High
$25.71
$52.93

Technical Indicators

Market Signals
Indicator
HAWK
RAPP
Relative Strength Index (RSI) 30.59 30.83
Support Level N/A $25.90
Resistance Level $17.42 $28.42
Average True Range (ATR) 0.64 2.24
MACD 0.02 0.05
Stochastic Oscillator 30.89 14.34

Price Performance

Historical Comparison
HAWK
RAPP

About HAWK HawkEye 360 Inc. Common Stock

Hawkeye 360 Inc operates in the signals intelligence (SIGINT) and defense technology sector. It provides end-to-end signals intelligence solutions integrated into national security systems for the United States and allied customers. Its offerings include radio frequency data and related insights to support defense operations. The company is involved across the value chain, including satellite design and manufacturing, data collection, and data processing and analysis. It generates revenue prominently from fixed price contract arrangements for RF signal mapping products that are used to analyze and track radio waves.

About RAPP Rapport Therapeutics Inc.

Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.

Share on Social Networks: